title: Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?
abstract: Diffuse large B-cell lymphoma presents as limited-stage disease in approximately 30% of cases. Historically, therapy relied on a combined modality of abbreviated chemotherapy followed by involved-field radiotherapy (IFRT). Due to the apparent lack of long-term survival and the concern for delayed toxicity, chemotherapy-only strategies are used more frequently. Treatment should take into account patient performance, clinical risks, and involvement sites. PET-guided approaches are being investigated. The risk of late relapse has been recognized, highlighting the importance of long-term follow-up. Future efforts must incorporate biological features to improve risk assessment, guide clinical decisions, and achieve an individualized therapy.
authors.affiliation: Hospital Clínic of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Carrer del Rosselló, 08036 Barcelona, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Giné
authors.affiliation: Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, 600 West 10th avenue, Vancouver, BC V5Z 4E6, Canada. Electronic address: Lsehn@bccancer.bc.ca.
authors.forename: Laurie H
authors.initials: LH
authors.lastname: Sehn
mesh_terms: D000359:Aftercare; D059248:Chemoradiotherapy / Q000379:methods*; D018572:Disease-Free Survival; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D057285:Precision Medicine / Q000379:methods*; D012307:Risk Factors; D015996:Survival Rate
keywords: Immunotherapy; Late relapses; Limited-stage DLBCL; Radiotherapy; Risk factors